Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 10
1947 20
1948 16
1949 10
1950 19
1951 37
1952 27
1953 33
1954 18
1955 32
1956 34
1957 19
1958 20
1959 36
1960 26
1961 37
1962 27
1963 46
1964 70
1965 57
1966 37
1967 35
1968 42
1969 50
1970 44
1971 59
1972 54
1973 61
1974 41
1975 45
1976 60
1977 46
1978 69
1979 61
1980 58
1981 67
1982 61
1983 68
1984 71
1985 68
1986 67
1987 71
1988 69
1989 78
1990 77
1991 84
1992 109
1993 113
1994 115
1995 116
1996 123
1997 132
1998 128
1999 121
2000 153
2001 155
2002 143
2003 164
2004 194
2005 219
2006 245
2007 228
2008 268
2009 305
2010 283
2011 340
2012 372
2013 382
2014 373
2015 379
2016 407
2017 394
2018 375
2019 464
2020 516
2021 564
2022 558
2023 486
2024 185

Text availability

Article attribute

Article type

Publication date

Search Results

10,098 results

Results by year

Filters applied: . Clear all
Page 1
Topical ruxolitinib: A new treatment for vitiligo.
Tavoletti G, Avallone G, Conforti C, Roccuzzo G, Maronese CA, Mattioli MA, Quaglino P, Zalaudek I, Marzano AV, Ribero S, Alberti-Violetti S. Tavoletti G, et al. J Eur Acad Dermatol Venereol. 2023 Nov;37(11):2222-2230. doi: 10.1111/jdv.19162. Epub 2023 May 15. J Eur Acad Dermatol Venereol. 2023. PMID: 37147856 Review.
JAK-STAT pathway inhibitors in dermatology.
Miot HA, Criado PR, de Castro CCS, Ianhez M, Talhari C, Ramos PM. Miot HA, et al. An Bras Dermatol. 2023 Sep-Oct;98(5):656-677. doi: 10.1016/j.abd.2023.03.001. Epub 2023 May 23. An Bras Dermatol. 2023. PMID: 37230920 Free PMC article. Review.
Immunometabolism in the pathogenesis of vitiligo.
Lyu C, Sun Y. Lyu C, et al. Front Immunol. 2022 Nov 10;13:1055958. doi: 10.3389/fimmu.2022.1055958. eCollection 2022. Front Immunol. 2022. PMID: 36439174 Free PMC article. Review.
Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.
Diotallevi F, Gioacchini H, De Simoni E, Marani A, Candelora M, Paolinelli M, Molinelli E, Offidani A, Simonetti O. Diotallevi F, et al. Int J Mol Sci. 2023 Mar 3;24(5):4910. doi: 10.3390/ijms24054910. Int J Mol Sci. 2023. PMID: 36902341 Free PMC article. Review.
Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial.
Ezzedine K, Peeva E, Yamaguchi Y, Cox LA, Banerjee A, Han G, Hamzavi I, Ganesan AK, Picardo M, Thaçi D, Harris JE, Bae JM, Tsukamoto K, Sinclair R, Pandya AG, Sloan A, Yu D, Gandhi K, Vincent MS, King B. Ezzedine K, et al. J Am Acad Dermatol. 2023 Feb;88(2):395-403. doi: 10.1016/j.jaad.2022.11.005. Epub 2022 Nov 9. J Am Acad Dermatol. 2023. PMID: 36370907 Free article. Clinical Trial.
10,098 results
You have reached the last available page of results. Please see the User Guide for more information.